NIPT — TRISOMY Test (Non-Invasive Prenatal Testing)

Non-invasive prenatal testing (NIPT) at G-CENTRUM Olomouc analyses cell-free fetal DNA circulating in the mother's blood to screen for chromosomal conditions with 99% accuracy — far exceeding the 85–90% detection rate of standard combined screening. The clinic uses the TRISOMY test platform via SPADIA laboratory. A single blood draw from week 11 of pregnancy is all that is required; results are returned without any risk to the fetus (unlike amniocentesis or CVS). Four tiers of the test are available depending on how many conditions need to be screened.

Non-invasive prenatal testing (NIPT) analyses fragments of cell-free fetal DNA (cffDNA) that circulate in the maternal bloodstream from as early as 7–10 weeks of gestation. From approximately week 11, the fetal fraction is high enough for reliable analysis. G-CENTRUM Olomouc offers NIPT via the TRISOMY test platform run by SPADIA laboratory — a well-established Czech prenatal diagnostic laboratory. The test requires a single venous blood draw at the clinic. The sample is sent to SPADIA for next-generation sequencing (NGS) analysis, which counts chromosomal fragments and identifies over- or under-representation indicating aneuploidy. Results are reported with >99% sensitivity and specificity for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome) — the three most common chromosomal conditions detectable in the first trimester. Four test levels are available: **TRISOMY test (basic) — 9,600 Kč:** Screens for Trisomy 21, 18, and 13. Suitable for women seeking maximum accuracy for the most common aneuploidies at the lowest cost. **TRISOMY test XY — 9,900 Kč:** All of the above, plus fetal sex determination. Note that sex determination may not be reported in all clinical contexts — discuss with the attending physician. **TRISOMY test Plus — 12,900 Kč:** Extended chromosomal coverage including sex chromosome aneuploidies (monosomy X / Turner syndrome, XXX, XXY, XYY) and select microdeletion syndromes. **TRISOMY test Complete — 13,500 Kč:** Comprehensive panel covering all of the above plus additional microdeletion/microduplication syndromes and genome-wide copy number variants. NIPT is a screening test, not a diagnostic test. A positive result should be confirmed by invasive testing (CVS or amniocentesis) before any clinical decisions are made. A negative result is highly reassuring but cannot exclude all chromosomal or structural conditions — it is typically combined with the anatomical ultrasound at 20–22 weeks.